Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences

Targeting Cancer Stem Cells to Transform Cancer Therapies
- Cancer Stem Cells 2018


The success of the Cancer Stem Cells conferences has given us the prospect to bring the gathering one more time. Allied Academies hosted the “11th International Conference on Cancer Stem Cells and Oncology Research” during June 11-13, 2018 at Finnstown Castle Hotel, Newcastle Rd, Finnstown, Lucan, Co. Dublin, Ireland. The conference was focused on Cancer Stem Cells studies with the theme “Targeting Cancer Stem Cells to Transform Cancer Therapies”. The meeting engrossed a vicinity of comprehensive discussions on novel subjects like Cancer Treatment and Therapeutics, Cancer Stem Cells, Breast Cancer Stem Cells, Pancreatic Cancer Stem Cells, Ovarian Cancer Stem Cells, Colorectal Cancer Stem Cells etc.

The conference was embarked with an opening ceremony followed by Keynote sessions and followed by series of lectures delivered by both Honourable Guests and members of the Keynote forum. The adepts who promulgated the theme with their exquisite talk were:

  • William G. Thilly, Massachusetts Institute of Technology, USA
  • Dean Tang, Roswell Park Cancer Institute, USA
  • Ralf Huss, Definiens, Germany
  • Wei Qiang Gao, Shanghai Jiao Tong University, China
  • Yong Li, University of New South Wales, Australia
  • Philippe Juin, Université de Nantes, France
  • Ilio Vitale, Regina Elena National Cancer Institute, Italy
  • Guo-fu Hu, Tufts University, USA
  • Elaine M. Hurt, MedImmune LLC, USA
  • Jingfang Ju, Stony Brook University, USA
  • Maithili A. Athavale, Sathgen  Biotech, India
  • Miaofen G Hu, Tufts Medical Center, USA
  • Nitin TELANG, Palindrome Liaisons Consultants, USA
  • Seong -Jin Kim, Seoul National University, Korea
  • Soraia Fernandes, Italian Institute of Technology, Italy
  • Chann Lagadec, INSERM, France
  • Xianming Mo, Sichuan University,China
  • Frederic Hollande, The University of Melbourne, Australia
  • Atique U. Ahmed, Northwestern University, USA

Allied Academies offers its heartfelt appreciation to Organizing Committee Members, dexterous of field, various outside experts, company representatives and is obliged to other eminent personalities who interlaced with Allied Academies and supported the conference in every aspect, without which the conference would not have been possible.

Your rejoinder is our inspiration; keeping this motto in mind and being witnessed the triumph of Oncology Research 2018, Allied Academies would like to announce the commencement of the “12th International Conference on Cancer Stem Cells” to be held during March 15-17, 2019 at Rome, Italy. We welcome all the eminent researchers, students and delegate participants to take part in this upcoming conference to witness invaluable scientific discussions and contribute to the future innovations in the field of Cancer Stem Cells Research.


About Confrence

Established in the year 1997, Allied Academies Publication is an amalgamation of several esteemed academic and scientific associations known for promoting scientific temperament. 

Allied Academies invites all the participants from all over the world to attend "11th International Conference on Cancer Stem Cells and Oncology Research”, on June 11-13, 2018 in Dublin, Ireland which includes prompt keynote presentations, oral talks, poster presentations and exhibitions.

Cancer stem cells (CSCs) are cancer cells (found within tumors or haematological cancers) that possess characteristics associated with normal stem cells, specifically the ability to give rise to all cell types found in a particular cancer sample. CSCs are therefore tumorigenic (tumour-forming), perhaps in contrast to other non-tumorigenic cancer cells. CSCs may generate tumors through the stem cell processes of self-renewal and differentiation into multiple cell types. Such cells are hypothesized to persist in tumors as a distinct population and cause relapse and metastasis by giving rise to new tumors. Therefore, development of specific therapies targeted at CSCs holds hope for improvement of survival and quality of life of cancer patients, especially for patients with metastatic disease.


Cancer Stem Cells 2018 is a platform to fulfill the prevailing gaps in the transformation of this science of hope, to serve promptly with solutions to all in the need. Cancer Stem Cells 2018 will have an anticipated participation of 120+ delegates across the world to discuss the conference goal.

About Organizers:

Allied Academies is one of the leading Open Access publishers and organizers of international scientific conferences and events every year across USA, Europe & Asia.  Allied Academics  has so far organized 3000+ Global Allied Academics  Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business with 700+ peer-reviewed open access journals in basic science, health, and technology.

Scientific Sessions:

Cancer Stem Cells 2018 will encompass recent researches and findings in Cancer stem cells technologies, Cancer stem cells therapies and transplantations, current understanding of cell plasticity in cancer and other advancements in Cancer stem cells research and cell science. Cancer Stem Cells 2018 will be a great platform for research scientists and young researchers to share their current findings in this field of applied science. The major scientific sessions in Cancer Stem Cells 2018 will focus on the latest and exciting innovations in prominent areas of Cancer cell science and Cancer stem cells research.

Target Audience:

Eminent personalities, Directors, CEO, President, Vice-president, Organizations, Associations Heads and Professors, Research scientists, Cancer Stem Cell laboratory heads, Post-docs, Students other affiliates related to the area of Cancer Stem cells research, regenerative medicine can be as Target Audience.

Welcome Message

Allied Academies welcomes all the attendees, speakers, sponsor’s and other research expertise from all over the world to the "11th International Conference on Cancer Stem Cells and Oncology Research” (Cancer Stem Cells-2018) which is going to be held during June 11-13, 2018 in Dublin, Ireland. We are very much honored to invite you all to exchange and share your views and experience on Caner Stem Cells: Targeting Cancer Stem Cells to Transform Cancer Therapies.

Allied Academies Organizes Cancer Stem Cells-2018 conference along with 300+ Conferences across USA, Europe & Asia every year with support from 1000 more scientific societies and Publishes 400+ Open access journals which contains over 30000 eminent personalities as editorial board members.

We invite you to join us at the Cancer Stem Cells-2018, where you will be sure to have a meaningful experience with scholars from around the world. All members of the Cancer Stem Cells-2018 organizing committee look forward to meeting you in Dublin, Ireland.


Allied Academies International Conferences invites all the participants from all over the world to attend "11th International Conference on Cancer Stem Cells and Oncology Research" during June 11-13, 2018 at Dublin, Ireland which includes prompt keynote presentations, oral talks, poster presentations and Exhibitions.

Track: Cancer Stem Cells

Cancer stem cells are rare immortal cells within a tumour that can both self-renew by dividing and give rise to many cell types that constitute the tumour, and can therefore form tumors. Such cells have been found in various types of human tumors and might be attractive targets for cancer treatment.

Track: Cancer Stem Cells and Metastasis

Metastasis is the spread of a cancer or other disease from one organ or part of the body to another without being directly connected with it. When cancer cells break away from a tumour, they can travel to other areas of the body through the bloodstream or the lymph system. The lungs, liver, brain, and bones are the most common metastasis locations from solid tumors.

Track: Cancer Stem Cells and the Tumor Microenvironment

A growing body of evidence indicates that the tumor microenvironment contributes to tumor growth and viability, while significant advances are being made in the understanding of cancer stem cells and tumor initiating cells. The session will discuss on breaking developments on novel tumor-killing strategies and preclinical and clinical projects which are exploiting cancer stem cells, the inflammatory component of tumors, and the tumor microenvironment for therapeutic intervention.

Track: Bio-markers of Cancer Stem Cells

Bio-marker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition.

Track: Cancer Genomics & Metabolomics

The main concept and idea of oncogenomics are to check a new group of oncogenes or tumour suppressor genes that may give new areas of research into cancer diagnosis, predicting clinical outcome of cancers and new targets for cancer therapies.  Oncogenomics is a sub-field of genomics that characterizes cancer-associated or cancer-related genes. It focuses mainly on genomic, epigenomic and transcript alterations in cancer. The Gleevec, Herceptin and Avastin are the targeted cancer therapies which gave a new way for oncogenomics to elucidate new targets for cancer treatment. The metabolome represents the collection of all metabolites in a biological cell, tissue, organ or organism that are the end products of cellular processes and gives physiology of the given cell. One of the challenging aspects of systems biology and functional genomics is to integrate proteomic, transcriptomic, and metabolomic information which provide a better understanding of cellular biology.

 Track: Immune systems in stem cells and cancer

Immuno-oncology is the new and emerging field of cancer research that works to understand the interaction of the immune system with cancers cells and finds ways for the harness of the patient’s immune system to treat or prevent cancer. It targets only the immune system, not the cancer cells. Recent advances in our understanding of antigen recognition, presentation and the molecules involved in T and B cell activation have provided new and excited immunotherapeutic strategies which can be used against the cancer cells. Some success in animal models has been observed and some molecules are now being in clinical trials.

Track: Clinical research and trials in stem cells and cancer

Cancer research focuses on stem cells present in malignant tumors. Researchers believe current cancer treatments sometimes fail because they don't destroy the cancer stem cells. Think of cancer as a weed: the stem cells are the root while the remaining majority of the cells are the part of the weed above ground. If you remove only the leaves but not the root, the weed will grow back. The same is true for cancer: if you do not kill the cancer stem cells, the cancer is likely to return.

Track: Stem Cell Transplantation for Cancer

Stem cell transplant (also called peripheral blood stem cell transplant) is a treatment to try to cure some types of cancer, such as leukemia, lymphoma and myeloma. You have very high doses of chemotherapy, sometimes with whole body radiotherapy. This has a good chance of killing the cancer cells but also kills the stem cells in the bone marrow. Stem cell transplant means that you can have higher doses of treatment. So there may be more chance of curing the cancer than with standard chemotherapy.

Track: Cancer Stem Cells Epigenetics

Epigenetic alterations including DNA methylation and histone modifications are the key factors in the differentiation of stem cells into different tissue subtypes. The generation of cancer stem cells (CSCs) in the process of carcinogenesis may also involve similar kind of epigenetic reprogramming where, in contrast, it leads to the loss of expression of genes specific to the differentiated state and regaining of stem cell-specific characteristics. The most important predicament with treatment of cancers includes the non-responsive quiescent CSC.Characterizing the epigenetic marks of CSCs and the associated signalling cascades might help in developing therapeutic strategies against chemo-resistant cancers.

Track: Breast Cancer Stem Cells

Breast cancer stem cells - the first to be identified in a solid tumour - were discovered in 2003 by scientists at the U-M Comprehensive Cancer Center. U-M scientists found that just a few cancer stem cells are responsible for the growth and spread of breast cancer. Unless the cancer stem cells are destroyed, the tumour is likely to come back and spread malignant cells to other parts of the body, a process called metastasis

Track: Pancreatic Cancer Stem Cells

Pancreatic cancer stem cells have some similarities to cancer stem cells found in other types of cancer; however, there also appear to be some significant differences. This is why it is important to study the function of these cells in the specific cancer in which these cells arise to best understand their function. Regardless of the organ in which they are found, cancer stem cells appear to be responsible for the propagation of cancer and for its spread to other organs in the body. 

Track: Embryonic Stem Cells

Embryonic stem cells (ES cells) are pluripotent stem cells derived from the inner cell mass of a blastocyst, an early-stage preimplantation embryo. Human embryos reach the blastocyst stage 4–5 days post fertilization, at which time they consist of 50–150 cells. Isolating the embryo blast or inner cell mass (ICM) results in destruction of the blastocyst, which raises ethical issues, including whether or not embryos at the pre-implantation stage should be considered to have the same moral or legal status as more developed human beings.

Track: Cancer Stem Cells in Brain Gliomas

Glioblastoma (GBM) is the most prevalent and malignant primary brain tumor and contains self-renewing, tumorigenic cancer stem cells (CSCs) that contribute to tumor initiation and therapeutic resistance. As normal stem and progenitor cells participate in tissue development and repair, these developmental programs re-emerge in CSCs to support the development and progressive growth of tumors.

Track: Hematopoietic and Chord blood stem cells

Cord blood stem cells are derived from the blood found in the vein of the umbilical cord. Cord blood contains immunologically naïve, hematopoietic stem cells known as HSCs which have been used in medical treatments for 25 years. They are capable of generating the multitude of cell types found in the bloodstream, including red blood cells or erythrocytes; different types of white blood cells, such as lymphocytes and neutrophils; and megakaryocytes which ultimately form platelets.

Track: Lung Cancer Stem Cells

Lung cancer remains a major cause of cancer-related lethality because of high incidence and recurrence in spite of significant advances in staging and therapies. Recent data indicates that stem cells situated throughout the airways may initiate cancer formation. These putative stem cells maintain protumorigenic characteristics including high proliferative capacity, multipotent differentiation, drug resistance and long lifespan relative to other cells. Stem cell signalling and differentiation pathways are maintained within distinct cancer types, and destabilization of this machinery may participate in maintenance of cancer stem cells. Characterization of lung cancer stem cells is an area of active research and is critical for developing novel therapies. This review summarizes the current knowledge on stem cell signalling pathways and cell markers used to identify the lung cancer stem cells.

Track: Prostate Cancer Stem Cells

Prostate Cancer is now a common disease in men over 50 years of age. Medical therapies for prostate cancer are based on discoveries from the mid-twentieth century, and in the long term are rarely curative. Most treatments are directed towards an androgen receptor-expressing, highly proliferative target cell, which does indeed form the vast majority of cells in a prostate tumour. However, by invoking the existence of a cancer stem cell which, like normal epithelial stem cells in the prostate, does not express androgen receptor and is relatively quiescent, the observed resistance to most medical therapies can be explained. The phenotype of the prostate cancer stem cells is that of a basal cell and cultures derived from cancers, but not benign tissues, express a range of prostate cancer-associated RNAs.

Track: Cancer Stem Cells in Solid Tumors

Cancer stem cells (CSCs) are cells that drive tumorigenesis, as well as giving rise to a large population of differentiated progeny that make up the bulk of the tumour, but that lack tumorigenic potential.

Track: Gynaecology oncology

Cervical Cancer is one of the most common cancers in women worldwide. But in the United States and other countries where cervical cancer screening is routine, this cancer is not so common. Most cervical cancer is caused by a virus called Human papillomavirus or also spelled as HPV. There are many types of the HPV virus, but all of HPV does not cause cervical cancer. Some of them cause genital warts, but other types may not show any Cervical Cancer symptoms and signs. An infection may go away on its own. But sometimes it can cause genital warts or can also lead to cervical cancer, it's important for women to have regular Pap tests. A Pap test can find changes in cervical cells before they turn into cancer cells. Thus treatment of these cell changes, prevent cervical cancer.

Track: Pediatric oncology

Pediatic Oncology is a branch of medicine which deals with the medical care of infants, children, and adolescents. The word pediatrics and its cognates mean "healer of children"; they derive from two Greek words: pais "child" and iatros "doctor, healer". The age limit, from birth up to 18-21 yrs. Pediatricians work both in primary care physicians and hospitals, especially they works in a specialized subfields such as neonatology. Paediatric oncologists diagnose, treat, and manage children, suffering from cancers which include leukaemia, lymphomas, brain tumours, bone tumours, and solid tumors. A medical practitioner who specializes in this area is called as a paediatrician. The body of an infant or neonate is substantially physiologically different when compare to an adult. Congenital defects, genetic variance and developmental issues are some greater concern to paediatricians as compare to adult physicians.

Track: Neuro Oncology

Neuro oncology is the study of brain and spinal cord neoplasms, which are very dangerous and leads to risking of life. Some of them are astrocytoma a type of brain cancer; glioma is type of tumor starts at brain or spine, glioblastoma which is also called as glioblastoma multiforme (GBM), ependymoma, pontine glioma, and brain stem tumors. Brain tumors can occur at any age of an individual, from primary stage to late in life. Most of the primary tumours are found common in women. A person who is trained in the diagnosis and treatment of nervous system is known as Neuro oncologist. Primary malignant brain tumours are found 5,000 people in UK each year and others are found with secondary tumours.

Track: Carcinogenesis and Mutagenesis

Carcinogenesis also called as oncogenesis or tumorigenesis, leads to formation of a cancer, where normal cells are turned into cancerous. Thus the process is characterized by changes at epigenetic, genetic and cellular levels. The main idea of carcinogenesis is to check new group of oncogenes or tumour suppressor genes that may give new areas of research into cancer diagnosis, predicting clinical outcome of cancers and new targets for cancer therapies. There are also many epigenetic changes that alter whether genes are expressed or not expressed. The presence of an abnormal number of chromosomes in a gene is known as Aneuploidy. It is a genomic change, not a mutation. Large-scale mutations involve the deletion or gain of a portion of a chromosome. Genomic amplification occurs only when cell gains 20 or more than 20 copies of a small chromosomal region, containing one or more oncogenes and apart to it adjacent genetic material. Mutagenesis is a process by which, genetic information of an species or an organism is changed and thus results in a mutation and can lead to cancer and various heritable diseases, done by physical, chemical or biological agents. In the laboratories, Mutagenesis plays an important technique where, DNA mutations are intentionally engineered so that they can produce mutant strains, proteins, or Gene of an organism.

Track: Radiation Oncology

The use of radiation to treat cancer is defined as Radiation Oncology. X-rays, gamma rays, or electrons are some of the radiations used to treat the Radiation Oncology. A physician who uses ionizing radiation (such as megavoltage X-rays or radionuclides) in the treatment of cancer is known as Radiation Oncologist. Thus Oncologists uses radiation to treat some of the benign diseases and benign tumours. Radiation oncology is one of the primary specialties among surgical and medical oncology, which are involved in the treatment of cancer. The field of radiation oncology gives the integration of radiation therapy into multimodal treatment approaches. Radiation Oncology focuses on all aspects of research, which impacts on the treatment of cancer using radiation. It not only shows findings in molecular and cellular radiation biology but also in wide range of radiation physics, radiation technology, and clinical oncology.

Track: Hemato-oncology and Blood Cancers

Hematologic oncology is the branch of medicine which deals with the study, diagnosis, treatment, and prevention of many diseases related to blood. Haematology involves the study of etiology. It involves the treatment of diseases which usually affect the production of blood and its components; it includes blood cells (RBC, WBC, etc…), haemoglobin, blood proteins, bone marrow, spleen, and also mechanism of coagulation. These kinds of diseases include hemophilia, blood clots, other bleeding disorders and mostly blood cancers such as leukaemia, myeloma, and lymphoma.  Blood cancers affect the production of most of the blood cells in the body. These types of cancers start in patient’s bone marrow where the blood is produced. Stem cells mature and develop into three types of blood cells, which are White blood cells, red blood cells or platelets; they are smallest type of blood cell present in the bone marrow. The normal growth of blood cell is stopped by the uncontrolled growth of abnormal blood cells, which are generally cancerous.

Track: Melanoma and other skin Cancer

Melanoma is one type of skin Cancer that arises when the melanocytes become cancerous. It is most common type of skin cancer but very serious if avoided. Melanoma, also called malignant melanoma, develops from the pigment-containing cells known as melanocytes. It typically occurs in the skin and rarely in the mouth, intestines, or eye. Individuals with low levels of skin pigment when expose to ultra violet light causes Melanoma. The use of sunscreen and avoiding UV light may prevent melanoma disease to a larger extent. Further treatment removal by surgery. Skin cancers are majorly arises from the skin. They are mainly due to abnormal growth of the cells that have the ability to spread to all other parts of the body of an individual. Basal-cell skin cancer (BCC), squamous-cell skin cancer (SCC) and melanoma are the common types of skin cancer seen in most of the individuals. Among these three BCC and SCC are commonly known as non-melanoma skin cancer (NMSC). Thus the non-melanoma skin cancer can be easily cured.

Market Analysis Report

Global Market Study of Cancer Stem Cells:

USA: According to a report published by W.H.O cancer fatalities are expected to increase from 14 million in 2012 to 22 million in 2020, 8.2 million deaths worldwide were due to cancer, colorectal cancer constituted 8.4%, breast cancer constituted 6.0% and liver constituted 9.0% in 2012.

Europe: Global Cancer stem cell market is expected to grow at a CAGR of 23% for the forecasted period of 2015-2020. Cancer Stem cell research is also being used to study genetic disorders, birth defects and other growth factors. 

Middle East: Cancer Stem Cell Therapy was conditionally approved in Canada in 2012. Mesenchymal Stem Cells are purified from the marrow, cultured and packaged, with up to 10,000 doses derived from a single donor. The doses are stored frozen until needed.

Asia Pacific: According to a new market research report, ‘Global Cancer Stem Cell Market – Growth, Trends & Forecasts (2015-2020)’, published by Mordor Intelligence, the Global market is expected to be worth US$ 30.25 billion by the end of 2020, The Global market for Stem Cells is expected to grow at a CAGR of 13.7% during the period of (2015-2020). 
Organizing Committee
OCM Member
Jinsong Liu
Professor, M. D. Anderson Cancer Center
The University of Texas
Houston, USA
OCM Member
Chann Lagadec
Assistant Professor /Chargé de Recherche, Cell Plasticity and Cancer, INSERM
French National Institute of Health and Medical Research
Paris, France
OCM Member
Philippe Juin
Director of Research
Center for Research in Cancerology and Immunology Nantes-Angers (CRCINA)
Nantes, France
OCM Member
Thierry Virolle
Research Director, Cancer Stem Cell Plasticity and Functional intra-tumor Heterogeneity
Institut de Biologie Valrose- Ibv
Nice, France
OCM Member
Ralf Huss
Stuttgart, Germany
OCM Member
Jingfang Ju
Stony Brook University
New York, USA
OCM Member
Dean G Tang
Roswell Park Cancer Institute
Newyork, USA
OCM Member
Xianming Mo
Director , Stem Cell Biology
West China Hospital of Sichuan University
Gungzhou, China
OCM Member
Ilio Vitale
Principal Investigator, Adjunct Professor in Neurobiology, Department of Biology
The University of Rome Tor Vergata
Rome, Italy
OCM Member
Jiangwen Zhang
Associate Professor , School of Biological Sciences
The University of Hong Kong
Hong Kong, China
OCM Member
Qi-En Wang
The Ohio State University
Columbus, USA
OCM Member
Joo-Hyeon Lee
Department of Zoology, University of cambridge
Exeter, United Kingdom
OCM Member
Claire Acquaviva
Marseille Cancer Research Centre
Marseille, France
OCM Member
Elaine Hurt
Gaithersburg, USA
OCM Member
Yong Li,
University of New South Wales
Kensington, Australia
OCM Member
Guo-fu Hu
Tufts University
Medford, USA
OCM Member
Emmanuelle Charafe-Jauffret
Institut Paoli-Calmettes
Marseille, France
OCM Member
Hervé Chneiweiss
Université Pierre et Marie Curie
Montpellier, France
OCM Member
Emilie Mamessier
Marseille Cancer Research Centre
Marseille, France
OCM Member
Stephen Maher
Trinity College Dublin
Dublin, Ireland
OCM Member
Laurie J Gay
Student Ambassador
The Francis Crick Institute
London, United Kingdom
Scientific Program

Finnstown Castle Hotel Newcastle Road, Lucan, Co. Dublin


Join The Discussion

Allied Academies Global Conference Directory

Mail us at

Program enquiry
General Queries
More details about

Terms and Conditions


Delegates are personally responsible for their belongings at the venue. The Organizers will not be held responsible for any stolen or missing items belonging to Delegates, Speakers or Attendees; due to any reason whatsoever.


Registration fees do not include insurance of any kind.


Please note that any (or) all transportation and parking is the responsibility of the registrant.


Press permission must be obtained from Allied Academies Conference Organizing Committee prior to the event. The press will not quote speakers or delegates unless they have obtained their approval in writing. The Allied Academies is an objective third-party nonprofit organization. This conference is not associated with any commercial meeting company.

Requesting an Invitation Letter

For security purposes, letter of invitation will be sent only to those individuals who had registered for the conference. Once your registration is complete, please contact to request a personalized letter of invitation.

Regarding refunds, all bank charges will be for the registrant's account.

All cancellations or modifications of registration must be made in writing to

Cancellation Policy

If Allied Academies cancels this event for any reason, you will receive a credit for 100% of the registration fee paid. You may use this credit for another Allied Academies event which must occur within one year from the date of cancellation.


If Allied Academies postpones an event for any reason and you are unable or unwilling to attend on rescheduled dates, you will receive a credit for 100% of the registration fee paid. You may use this credit for another Allied Academies event which must occur within one year from the date of postponement.

Transfer of registration

All fully paid registrations are transferable to other persons from the same organization if registered person is unable to attend the event. Transfers must be made by the registered person in writing to . Details must be included the full name of replacement person, their title, contact phone number and email address. All other registration details will be assigned to the new person unless otherwise specified.

Registration can be transferred to one conference to another conference of Allied Academies if the person is unable to attend one of the conferences.

However, Registration cannot be transferred if it is intimated within 14 days of the respective conference.

The transferred registrations will not be eligible for Refund.

Visa Information

Keeping in view of increased security measures, we would like to request all the participants to apply for Visa as soon as possible.

Allied Academies will not directly contact embassies and consulates on behalf of visa applicants. All delegates or invitees should apply for Business Visa only.

Important note for failed visa applications: Visa issues cannot come under the consideration of cancellation policy of Allied Academies, including the inability to obtain a visa.

Refund Policy:

If the registrant is unable to attend and is not in a position to transfer his/her participation to another person or event, then the following refund arrangements apply:

Keeping in view of advance payments towards Venue, Printing, Shipping, Hotels and other overheads, we had to keep Refund Policy is as following slabs-

  • Before 60 days of the conference: Eligible for Full Refund less $100 service Fee
  • Within 60-30 days of Conference: Eligible for 50% of payment Refund
  • Within 30 days of Conference: Not eligible for Refund
  • E-Poster Payments will not be refunded.

Accommodation Cancellation Policy:

Accommodation Providers (Hotels) have their own cancellation policies, and they generally apply when cancellations are made less than 30 days prior to arrival. Please contact us as soon as possible, if you wish to cancel or amend your accommodation. Allied Academies will advise the cancellation policy of your accommodation provider, prior to canceling or amending your booking, to ensure you are fully aware of any non-refundable deposits.

Highlights from last year's Convention

Authorization Policy

Copyright © 2020-2021 Allied Academies, All Rights Reserved.